K/B×N serum transfer arthritis is delayed and less severe in leukaemia inhibitory factor (LIF)-deficient mice
Publication Details
Upadhyay, A., Senyschyn, D., Santos, L., Gu, R., Carroll, G. J. , & Jazayeri, J. A. (2012). K/B×N serum transfer arthritis is delayed and less severe in leukaemia inhibitory factor (LIF)-deficient mice. Clinical and Experimental Immunology, 169(2), 71–78. doi:10.1111/j.1365-2249.2012.04601.x
Abstract
This study is investigating the role of leukaemia inhibitory factor (LIF) in the development of inflammation and joint damage in the mouse K/B×N serum transfer arthritis model. LIF knock-out (LIF−/−) mice were generated by mating heterozygote females (LIF+/−) with heterozygote males. Arthritis was induced in 8–20-week-old LIF knock-out mice (LIF−/−) by intraperitoneal injection of pooled K/B×N sera (50 µl) on days 0 and 2. Clinical disease was scored daily for 6 days. Safranin-O and haematoxylin-stained sections were scored for synovitis, joint space exudate, cartilage degradation and bone damage. RNA was extracted from ankle joints and used to investigate gene expression levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1, LIF, LIF receptor, oncostatin M (OSM), OSM receptor, IL-6 and their common receptor subunit gp130 by quantitative reverse transcription–polymerase chain reaction (qRT–PCR). The results show that wild-type mice developed severe clinically overt polyarthritis. In contrast, LIF−/− mice showed a more than 50% reduction in clinical arthritis severity. Significantly lower histological scores were observed in LIF−/− mice compared to wild-type disease controls. LIF−/− mice had histopathological scores that were similar to normal healthy mice. IL-6 subfamily cytokine and receptor subunit expression remained unchanged. The expression levels for IL-6 were reduced significantly in all the diseased mice, whether wild-type or LIF−/− mice (P < 0·001), compared to healthy wild-type mice. We conclude that LIF contributes to the development of disease in the K/B×N serum transfer model of arthritis. These results provide further evidence for the role of LIF in inflammation and cartilage bone resorption and provide impetus to test the effects of LIF blockade as a therapeutic strategy in rheumatoid arthritis.
Keywords
peer-reviewed
